We are live on
!
Find out more
ACM
Atika Capital Management Portfolio holdings
AUM
$796M
1-Year Est. Return
167.57%
This Fund
S&P 500
This Quarter
Est. Return
+27.6%
1 Year Est. Return
+167.57%
3 Year Est. Return
+553.47%
5 Year Est. Return
+1,283.26%
10 Year Est. Return
+44,203.78%
AUM
$950M
AUM Growth
-$292M
(-24%)
Cap. Flow
-$566M
Cap. Flow
% of AUM
-59.62%
Top 10 Holdings %
Top 10 Hldgs %
46.71%
Holding
121
New
35
Increased
14
Reduced
21
Closed
44
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Madrigal Pharmaceuticals
MDGL
|
+$17.4M |
| 2 |
Cogent Biosciences
COGT
|
+$14.2M |
| 3 |
Teva Pharmaceuticals
TEVA
|
+$12.1M |
| 4 |
Alphabet (Google) Class C
GOOG
|
+$12.1M |
| 5 |
HEICO Corp
HEI
|
+$8.31M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$85.5M |
| 2 |
Amazon
AMZN
|
+$72.5M |
| 3 |
Spotify
SPOT
|
+$43.9M |
| 4 |
Martin Marietta Materials
MLM
|
+$43.2M |
| 5 |
Arista Networks
ANET
|
+$33.7M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 26.3% |
| 2 | Industrials | 20.32% |
| 3 | Consumer Discretionary | 9.92% |
| 4 | Technology | 9.36% |
| 5 | Communication Services | 5.34% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
101
Mineralys Therapeutics
MLYS
$2.41B
| – | – |
-174,000
| Closed | -$6.6M |
|
|
102
Microsoft
MSFT
$3.71T
| – | – |
-165,000
| Closed | -$85.5M |
|
103
Natera
NTRA
$46.4B
| – | – |
-46,497
| Closed | -$7.48M |
|
104
NVIDIA
NVDA
$5.42T
| – | – |
-73,900
| Closed | -$13.8M |
|
105
uniQure
QURE
$3.22B
| – | – |
-90,000
| Closed | -$5.25M |
|
106
CALL
Ultragenyx Pharmaceutical
RARE
$2.55B
| – | – |
-500
| Closed | -$1.5M |
|
107
Roblox
RBLX
$27B
| – | – |
-142,500
| Closed | -$19.7M |
|
108
RxSight
RXST
$260M
| – | – |
-354,907
| Closed | -$3.19M |
|
109
SiriusPoint
SPNT
$2.68B
| – | – |
-260,000
| Closed | -$4.7M |
|
|
110
Spotify
SPOT
$100B
| – | – |
-62,870
| Closed | -$43.9M |
|
111
STAAR Surgical
STAA
$1.21B
| – | – |
-16,400
| Closed | -$441K |
|
112
CALL
Seagate
STX
$184B
| – | – |
-234
| Closed | -$5.52M |
|
113
Unity
U
$18.9B
| – | – |
-80,000
| Closed | -$3.26M |
|
|
VRNA
114
DELISTED
Verona Pharma
VRNA
| – | – |
-176,000
| Closed | -$18.8M |
|
115
Vistra
VST
$47.4B
| – | – |
-123,000
| Closed | -$24.1M |
|
116
Zura Bio
ZURA
$566M
| – | – |
-276,000
| Closed | -$1.2M |
|
117
GE Vernova
GEV
$264B
| – | – |
-42,439
| Closed | -$26.1M |
|
|
NBIS
118
Nebius Group N.V.
NBIS
$47.7B
| – | – |
-179,880
| Closed | -$20.2M |
|
|
CAI
119
Caris Life Sciences
CAI
$6.43B
| – | – |
-25,000
| Closed | -$756K |
|
|
HTFL
120
Heartflow Inc
HTFL
$2.49B
| – | – |
-69,000
| Closed | -$2.32M |
|
|
NTSK
121
Netskope Inc
NTSK
$6.01B
| – | – |
-114,000
| Closed | -$2.59M |
|
Similar funds
AGA
ACM
LSA
GWA
HP
SC
IAM
VCM
Atika Capital Management's Q4 2025 Portfolio in Review
As of Q4 2025, Atika Capital Management held 121 positions worth $950M, down 24% from $1.24B the previous quarter. Its ten largest holdings account for 47% of the portfolio.
Atika Capital Management withdrew a net $566M in Q4 2025, closing 44 positions and reducing 21 holdings. Its most notable exit was Microsoft, an estimated $85.5M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 26% of assets, up from 17% a quarter earlier, followed by Industrials and Consumer Discretionary.
Against the trend, Atika Capital Management opened a new position in Madrigal Pharmaceuticals worth $19.8M.
- Atika Capital Management's largest Q4 2025 buy was Madrigal Pharmaceuticals: 34,000 shares worth $19.8M.
- Atika Capital Management added most to Teva Pharmaceuticals in Q4 2025, an estimated $12.1M increase.
- Atika Capital Management's biggest Q4 2025 reduction was Amazon, cutting an estimated $72.5M.
- Atika Capital Management fully exited Microsoft in Q4 2025, selling an estimated $85.5M.
- Atika Capital Management's ten largest holdings make up 47% of its $950M portfolio in Q4 2025.
- Atika Capital Management opened 35 new positions and closed 44 in Q4 2025.
- Atika Capital Management's portfolio value fell 24% quarter-over-quarter to $950M.
Based on Atika Capital Management's 13F filing for Q4 2025, filed 13 Feb 2026.